The company added that ISIS-SOD1Rx is part of its strategic collaboration with Biogen to discover and develop antisense drugs
to treat neurological diseases, including ALS, a rare, fatal neurodegenerative disorder.
Isis inventions in oligonucleotide chemistry enable improved stability, potency, distribution and safety of antisense drugs
and are the basis for a portion of the company's industry-leading intellectual property position.
The extended collaboration also provides Lilly access to Isis patents to support Lilly's internal antisense drug
discovery program for a limited number of targets.
The promise of antisense drugs
lies in the theory that they work on a specific target disease without causing significant side effects.
Second-generation antisense drugs
offer greater potency, enhanced tolerability, and improved dosing convenience compared to first-generation antisense drugs
are short, chemically-modified RNA-like and DNA-like molecules that scientists design to complement a small, specific segment of messenger RNA.
Amgen and Isis are collaborating to discover and develop new antisense drugs
utilizing Isis' proprietary second-generation chemistry, called 2'-O-methoxyethyl.
In 2010, Isis entered into collaboration with Xenon to discover and develop antisense drugs
as novel treatments for ACD.
a San Diego-based biotechnology company, to develop so-called antisense drugs
to block the activity of bcl-2.
The potential market for antisense drugs
is huge, they gush -- about $25 billion by 1992, according to some company estimates.
AVI's proprietary NEUGENE antisense drug
candidates have demonstrated efficacy in preclinical studies against SARS coronavirus, West Nile virus (WNV), hepatitis C virus (HCV), dengue virus, Ebola virus and Marburg virus.
Isis Pharmaceuticals Inc (NASDAQ: ISIS), an antisense technology company, revealed on Monday that it has earned a milestone payment of USD10m from biopharmaceutical company AstraZeneca, in association with the addition of the antisense drug
ISIS-ARRx as a second development candidate in a collaboration between the two companies.
AVI-4557 is a NEUGENE antisense drug
designed to silence the expression of CYP3A4.
Isis said that its infringement suit against Santaris is based upon Santaris' activities providing antisense drugs
and antisense drug
discovery services to several pharmaceutical companies.
Nasdaq:AVII), today announced the initiation of a clinical program to assess the safety and effectiveness of AVI-5126, a new generation of NEUGENE([R]) antisense drug
for treating coronary vascular disease.